Preoperative Daptomycin Prophylaxis for Preventing Gram-Positive or Methicillin-Resistant Staphylococcus Aureus Infection in Two-Stage Exchange Arthroplasty: A Prospective, Randomized, Double-Blinded Trial

The gold standard for treating prosthetic joint infection (PJI) is two-stage exchange arthroplasty. This includes the first stage of debridement and removal of the artificial joint, and the second stage of reimplantation of the artificial joint. Methicillin-resistant staphylococcus aureus (MRSA) infection is one of the factors leading to the failure of artificial joint infection treatment. Before the second stage of the joint surgery, the surgeon will prescribe prophylactic antibiotics based on previous bacterial cultures. The usual preoperative antibiotic is a first-generation cephalosporin antibiotic. If it is MRSA, vancomycin will be given. Increasingly, literature reports link prosthetic joint infections to MRSA, but no changes have been made to the routine recommendation for MRSA prophylactic antibiotic use.
Daptomycin is a cyclic lipopeptide antibiotic that can rapidly penetrate biofilms and bones, and its safety and tolerability have been confirmed. Therefore, it can effectively combat Gram-positive organisms, including MRSA. Daptomycin has many characteristics of an ideal prophylactic: short infusion time, low adverse events during administration, and a range limited to Gram-positive organisms. We aim to assess whether adding antibiotics that cover MRSA would reduce prosthetic joint infections and increase surgical success rates, in addition to the standard recommended prophylactic antibiotics. Thus, this prospective randomized trial is designed to assess, besides using the first-generation cephalosporin antibiotic, the effects of adding an antibiotic with MRSA coverage (Daptomycin vs. Vancomycin).

Start Date01 Aug 2024

Sponsor / Collaborator

Chang Gung Memorial Hospital

NCT04983901 / CompletedPhase 2IIT

An Investigator Initiated, Phase II Single-Center, Randomized, Open-Label, Prospective, Study To Determine The Impact Of Serial Procalcitonin On Improving Antimicrobial Stewardship And On The Efficacy, Safety, And Tolerability Of Imipenem-Cilastatin-Relebactam Plus/Minus Vancomycin Or Linezolid Versus Standard Of Care Antipseudomonal Beta-Lactams Plus/Minus Vancomycin Or Linezolid As Empiric Therapy In Febrile Neutropenic Adults With Cancer

This phase II trial studies the effect of imipenem-relebactam in treating patients with cancer who have a fever due to low white blood cell counts (febrile neutropenia). In this study, imipenem-relebactam will be compared to the standard-of-care treatment (cefepime, meropenem, or piperacillin/tazobactam) for the treatment of febrile neutropenia. Imipenem-relebactam is used to treat infections. Giving imipenem-relebactam may help to control febrile neutropenia in patients with cancer.

Start Date14 Sep 2021

Sponsor / Collaborator

The University of Texas MD Anderson Cancer Center

[+1]

NCT04277143 / Unknown statusNot Applicable

The Influence Factors of Pharmacokinetics/Pharmacodynamics of Daptomycin in Severe Patients and the the Effect of Different Blood Concentration of Daptomycin on the Outcomes of Renal Function

Daptomycin ，is the ﬁrst approved member of a new class of antimicrobials, the cyclic lipopeptides, and presents selective action against gram-positive bacteria, including methicillin- and vancomycin-resistant strains，disrupting the transfer of amino acids in the cell membrane, thus hindering the biosynthesis of bacterial cell cell wall peptide polysaccharide, changing the properties of cytoplasm membrane, can destroy bacterial cell membrane function in many ways, and quickly kill gram-positive bacteria. Because of its unique chemical structure and sterilization mechanism, bacteria rarely develop resistance to daptomycin. Daptomycin can be reversibility combined with human plasma protein (mainly serum albumin) and metabolized mainly through the kidneys.
There is still a lot of controversy about the application of daptomycin in patients with severe illness. Although studies suggest that daptomycin has less damage to kidney function than vancomycin, the effect of daptomycin on kidney function in severely ill patients is not yet clear, and more clinical studies are needed to explore their relationship. In addition, it is not clear whether the physiological pathology of specific populations such as sepsis/infectious shock, acute kidney injury, (AKI), hypoproteinemia, and renal replacement treatment affects the pharmacokinetics/pharmacodynamics of Daptomycin.
By exploring the application of daptomycin in patients with severe illness, this study explores the effects of special pathological physiological states such as sepsis/infectious shock and hypoproteinemia on daptomycin PK/PD, as well as the effects of different hemoglobin concentrations of daptomycin on the outcome of kidney function.

Start Date01 Dec 2020

Sponsor / Collaborator

Zhongnan hospital of wuhan university

100 Clinical Results associated with Daptomycin

100 Translational Medicine associated with Daptomycin

100 Patents (Medical) associated with Daptomycin

3,689

Literatures (Medical) associated with Daptomycin

bioRxiv : the preprint server for biology

Defective pgsA contributes to increased membrane fluidity and cell wall thickening in S. aureus with high-level daptomycin resistance

Author: Urbauer, Ramona ; Hines, Kelly M ; Hansen, Tayte ; Wilkinson, Brian J ; Singh, Vineet K ; Freeman, Christian D

ABSTRACT:

Daptomycin is a membrane-targeting last-resort antimicrobial therapeutic for the treatment of infections caused by methicillin- and/or vancomycin-resistantStaphylococcus aureus. In the rare event of failed daptomycin therapy, the source of resistance is often attributable to mutations directly within the membrane phospholipid biosynthetic pathway ofS. aureusor in the regulatory systems that control cell envelope response and membrane homeostasis. Here we describe the structural changes to the cell envelope in a daptomycin-resistant isolate ofS. aureusstrain N315 that has acquired mutations in the genes most commonly reported associated with daptomycin-resistance:mprF,yycG, andpgsA. In addition to the decreased phosphatidylglycerol (PG) levels that are the hallmark of daptomycin-resistance, the mutant with high-level daptomycin resistance had increased branched-chain fatty acids (BCFAs) in its membrane lipids, increased membrane fluidity, and increased cell wall thickness. However, the successful utilization of isotope-labeled straight-chain fatty acids (SCFAs) in lipid synthesis suggested that the aberrant BCFA:SCFA ratio arose from upstream alteration in fatty acid synthesis rather than a structural preference in PgsA. RT-qPCR studies revealed that expression of pyruvate dehydrogenase (pdhB) was suppressed in the daptomycin-resistant isolate, which is known to increase BCFA levels. While complementation with an additional copy ofpdhBhad no effect, complementation of thepgsAmutation resulted in increased PG formation, reduction in cell wall thickness, restoration of normal BCFA levels, and increased daptomycin susceptibility. Collectively, these results demonstrate thatpgsAcontributes to daptomycin resistance through its influence on membrane fluidity and cell wall thickness, in addition to phosphatidylglycerol levels.

IMPORTANCE:

The cationic lipopeptide antimicrobial daptomycin has become an essential tool for combating infections withStaphylococcus aureusthat display reduced susceptibility to β-lactams or vancomycin. Since daptomycin’s activity is based on interaction with the negatively charged membrane ofS. aureus, routes to daptomycin-resistance occur through mutations in the lipid biosynthetic pathway surrounding phosphatidylglycerols and the regulatory systems that control cell envelope homeostasis. Therefore, there are many avenues to achieve daptomycin resistance and several different, and sometimes contradictory, phenotypes of daptomycin-resistantS. aureus,including both increased and decreased cell wall thickness and membrane fluidity. This study is significant because it demonstrates the unexpected influence of a lipid biosynthesis gene,pgsA, on membrane fluidity and cell wall thickness inS. aureuswith high-level daptomycin resistance.

01 Feb 2024·Current microbiology

Population Analysis of Daptomycin-non-Susceptible Methicillin-Resistant Staphylococcus aureus Reveals the Presence of Variants That Contribute to Daptomycin Resistance

Article

Author: Yabuta, Junya ; Jitsukawa, Tomotaka ; Takahashi, Hiroshi ; Kanayama Katsuse, Akiko ; Fujisaki, Shingo ; Kobayashi, Intetsu ; Mikawa, Takashi ; Ohno, Akira ; Kanesaka, Izumo ; Morita, Masahiro

In this study, population analysis (PA) of methicillin-resistant Staphylococcus aureus (MRSA), before and after long-duration daptomycin (DAP) treatment, was used to detect subpopulations with different susceptibilities to DAP and to verify the changes in the number of resistant cells. Furthermore, we aimed to characterize the bacteriology of the variants present in the non-susceptible cell subpopulation. A DAP non-susceptible (NS) MRSA phenotype (D2) that emerged from a DAP- susceptible MRSA phenotype (D1) during treatment of an open wound, was used for testing. We performed bacteriological and genetic analyses of cryptic DAP-NS MRSA variants detected by PA to study the variants present in the resistant cell subpopulation. PA results suggest that MRSA adapted to survival in the presence of DAP are selected leading to reduced susceptibility. Within the cell population growing in media containing 2.0 mg/L of DAP, three variants with different pigment production and colony size were detected. Variant 3 was an orange colony due to enhanced production of staphyloxanthin. Our results revealed that the DAP minimum inhibitory concentration (MIC) value increased two-fold (4 mg/L) in variant 3, in which pigment production was most enhanced, compared to the parental strain D2. In conclusion, our results indicate that long-duration DAP treatment can lead to the emergence and increased proportion of DAP-NS subpopulations. Furthermore, slow-growing variants that can be detected only under antimicrobial selective pressure are present among DAP-NS cells, suggesting that these variants may also contribute to the development of DAP resistance.

01 Feb 2024·International journal of antimicrobial agents

Daptomycin non-susceptible Staphylococcus argenteus isolated from a patient without prior antibiotic exposure

Letter

Author: Coombs, Geoffrey W ; Daley, Denise A ; Shoby, Princy ; Lim, Candice ; Mowlaboccus, Shakeel

This article reports a daptomycin-resistant Staphylococcus argenteus from a patient without prior exposure to antimicrobials, including daptomycin or vancomycin.The organism was isolated from a 38-yr-old male with a chronic leg ulcer who had been admitted to Fiona Stanley Hospital, Western Australia.By disk diffusion, the isolate was susceptible to penicillin, oxacillin, erythromycin, clindamycin, trimethoprim-sulfamethoxazole, and vancomycin.This finding highlights the possibility of the spontaneous development of daptomycin non-susceptibility in S. argenteus clin. isolates without prior exposure to daptomycin.

News (Medical) associated with Daptomycin

11 Jun 2024

·www.sciencedaily.com

Novel lipopeptide proves lethal against Staphylococcus areus

Researchers provide the first insight into the mode of action of the lipopeptide serrawettin W2-FL10, derived from Serratia marcescens. This lipopeptide targets the cell membrane of S. aureus, causing lesions which result in the leakage of intracellular components and ultimately cell death. A novel antibacterial lipopeptide produced by the bacterium Serratia marcescens has been shown to be highly effective in killing Staphylococcus aureus -- one of the most important pathogens occurring in humans. Staphylococcus aureus is one of the five most common causes of hospital-acquired infections and is often the cause of life-threatening infections following surgery. Since the introduction of antibiotics in the early 1940s, S. aureus has by now developed resistance against most classes of antibiotics, including penicillin. However, over the last six decades, only two new classes of antibiotics with unique modes of action have been introduced onto the market. One of these, daptomycin, also belongs to the lipopeptide class of antibiotics. In a paper published in Microbiology Spectrum recently, Dr Tanya Decker (neé Clements) from Stellenbosch University (SU) provided the first insight into the mode of action of the lipopeptide serrawettin W2-FL10, derived from Serratia marcescens. She demonstrated that this lipopeptide targets the cell membrane of S. aureus, causing lesions which result in the leakage of intracellular components and ultimately cell death. She also demonstrated that serrawettin W2-FL10 is not toxic to mammalian cells, thereby making it a promising therapeutic agent for the treatment of bacterial infections in humans. Furthermore, as this lipopeptide's structure is much smaller than that of daptomycin (five amino acids and a C10 fatty acid chain compared to 13 amino acids and a C10 fatty acid chain), the manufacturing costs of serrawettin W2-FL10 would be significantly less. Why are some lipopeptides antimicrobial? Dr Decker, who is currently a postdoctoral researcher at the Helmholtz Institute for Pharmaceutical Research Saarland in Germany, started working on serrawettin W2-FL10 back in 2017 in the research group of Prof. Wesaal Khan in SU's Department of Microbiology. Her research followed the work done by another postgraduate student in this group, Dr Thando Ndlovu, who isolated various bacterial strains from wastewater samples whose biosurfactants proved effective against antibiotic-resistant and disease-causing bacteria. In polluted environments, biosurfactants are produced naturally by bacteria to protect them against and outcompete other bacteria. Decker's research then focused on understanding the antimicrobial activity of Serratia-derived lipopeptides. She focused primarily on pigmented and non-pigmented S. marcescens strains and demonstrated that these strains also produced a wide range of broad-spectrum antimicrobial compounds. From these findings, the lipopeptide serrawettin W2-FL10 was found to be a promising candidate for further investigation into its antimicrobial characteristics. Prof. Khan says the success of their findings thus far is also largely based on close collaboration with Prof. Marina Rautenbach, a biochemist and specialist in antimicrobial peptides, at SU's Department of Biochemistry. At the Helmholtz Institute in Germany, Decker is continuing her research into novel natural antimicrobial products.

Microbial therapyQualified Infectious Disease Product

06 May 2024

·www.globenewswire.com

Basilea reports presentation of new data for ceftobiprole (Zevtera®) at ESCMID Global 2024

Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that scientific presentations with new data on its antibiotic ceftobiprole (Zevtera®) have been presented at ESCMID Global 2024, the annual meeting of the European Society of Clinical Microbiology and Infectious Diseases, which took place from April 27 to 30, 2024 in Barcelona, Spain. Dr. Marc Engelhardt, Chief Medical Officer of Basilea, stated: “The data presented at ESCMID Global 2024 provide further evidence for the differentiated profile of ceftobiprole in the treatment of severe bacterial bloodstream infections, including those involving methicillin-resistant Staphylococcus aureus, MRSA, and pulmonary infections.” Ceftobiprole was recently approved by the US Food and Drug Administration (FDA), supported by data from three phase 3 studies: ERADICATE, conducted in patients with Staphylococcus aureus bacteremia (SAB), TARGET, in acute bacterial skin and skin structure infections (ABSSSI), and a study in community-acquired bacterial pneumonia (CABP).1, 2, 3 Additional data from the ERADICATE phase 3 study were presented in three posters, comparing ceftobiprole to daptomycin in the treatment of complicated Staphylococcus aureus bacteremia. One poster focused on subgroup analyses in patients with renal impairment, demonstrating consistent efficacy and safety of ceftobiprole in this specific patient group, which included patients with chronic dialysis, representing 13% of patients in the ERADICATE study. Furthermore, baseline characteristics of patients in the ERADICATE study were presented, underlining the complexity of the infections in the studied patient population, with about 30% of patients presenting with more than one underlying infectious condition, foci, or complications at baseline, including soft tissue infections, dialysis, abdominal and thoracic abscesses, osteoarticular infections and right-sided endocarditis. Data presented on a third poster demonstrated that bloodstream clearance was achieved at a median of four days after the start of treatment in both the ceftobiprole and comparator groups. In the group treated with ceftobiprole, fewer patients had Staphylococcus aureus-positive blood cultures after ten days compared to the comparator treatment group. An oral presentation focused on a re-analysis of the previously conducted ceftobiprole phase 3 study in patients with community-acquired bacterial pneumonia (CABP). The study compared ceftobiprole with ceftriaxone ± linezolid and was performed prior to the availability of the current FDA guidance for the development of drugs for the treatment of CABP (FDA-CABP-2020). Using the FDA-CABP-2020 primary endpoint of early clinical success at day 3 after study start, this re-analysis supported the non-inferiority of ceftobiprole to ceftriaxone ± linezolid. Basilea’s phase 3 program for ceftobiprole is funded in part with federal funds from the US Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response (ASPR); Biomedical Advanced Research and Development Authority (BARDA), under contract number HHSO100201600002C. Through this partnership, Basilea has been awarded approximately USD 112 million, or approximately 75 percent of the costs related to the SAB and ABSSSI phase 3 studies, regulatory activities and non-clinical work. Ceftobiprole, the active moiety of the prodrug ceftobiprole medocaril, is an advanced generation cephalosporin antibiotic for intravenous administration, with rapid bactericidal activity against a wide range of Gram-positive bacteria, such as Staphylococcus aureus, including methicillin-resistant strains (MRSA), and Gram-negative bacteria.4 In several countries in Europe and beyond, the brand is currently approved and marketed as Zevtera® and Mabelio® for the treatment of adult patients with hospital-acquired bacterial pneumonia (HABP), excluding ventilator-associated bacterial pneumonia (VABP), and for the treatment of community-acquired bacterial pneumonia (CABP). Basilea has entered into license and distribution agreements covering more than 80 countries. In the United States, ZEVTERA® is indicated for the treatment of adult patients with Staphylococcus aureus bloodstream infections (bacteremia) (SAB), including right-sided infective endocarditis, and adult patients with acute bacterial skin and skin structure infections (ABSSSI) and for adult and pediatric patients (3 months to less than 18 years old) with community-acquired bacterial pneumonia (CABP). Warnings and precautions Increased Mortality with Unapproved use in Ventilator-Associated Bacterial Pneumonia (VABP) Patients: The safety and effectiveness of ZEVTERA for the treatment of VABP has not been established and the use of ZEVTERA for VABP is not approved. Hypersensitivity Reactions: Discontinue ZEVTERA if a hypersensitivity reaction occurs, and institute appropriate treatment. Seizures and other adverse central nervous system (CNS) reactions have been associated with the use of ZEVTERA. If seizures or other CNS adverse reactions occur, evaluate patients to determine whether ZEVTERA should be discontinued. Clostridioides difficile-associated diarrhea (CDAD) has been reported with nearly all systemic antibacterial agents, including ZEVTERA. Evaluate if diarrhea occurs. Staphylococcus aureus bacteremia (SAB) is a serious bloodstream infection associated with significant morbidity and mortality.5 Complications include concomitant infections such as bone, joint or heart valve infections, persistent bacteremia or bacteremia in patients on dialysis. With a 30-day all-cause mortality of around 20%, there is a high medical need for improved therapies for SAB.6 Acute bacterial skin and skin structure infections (ABSSSI) are common infections in the healthcare setting. Staphylococcus aureus is the most common pathogen associated with these infections, which can be difficult to treat if methicillin-resistant Staphylococcus aureus (MRSA) is involved.7 Community-acquired bacterial pneumonia (CABP) is a leading cause of morbidity and mortality worldwide. It is the leading cause of infectious disease-related death in the US.8 Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland. We are committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with severe bacterial and fungal infections. We have successfully launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of bacterial infections. In addition, we have preclinical and clinical anti-infective assets in our portfolio. Basilea is listed on the SIX Swiss Exchange (SIX: BSLN). Please visit basilea.com. References ERADICATE study (SAB): ClinicalTrials.gov identifier NCT03138733 T. L. Holland, S. E. Cosgrove, S. B. Doernberg et al. Ceftobiprole for treatment of complicated Staphylococcus aureus bacteremia. New England Journal of Medicine 2023 (389), 1390-1401; DOI: 10.1056/NEJMoa2300220 TARGET study (ABSSSI): ClinicalTrials.gov identifier NCT03137173 J. S. Overcash, C. Kim, R. Keech et al. Ceftobiprole compared with vancomycin plus aztreonam in the treatment of acute bacterial skin and skin structure infections: Results of a phase 3, randomized, double-blind trial (TARGET). Clinical Infectious Diseases 2021 (73), e1507-e1517 CABP study: ClinicalTrials.gov identifier NCT00326287 S. C. Nicholson, T. Welte, T. M. File Jr. et al. A randomised, double-blind trial comparing ceftobiprole medocaril with ceftriaxone with or without linezolid for the treatment of patients with community-acquired pneumonia requiring hospitalization. International Journal of Antimicrobial Agents 2012 (39), 240-246 Summary of Product Characteristics (SmPC) Zevtera: https://www.medicines.org.uk/emc/product/9164/smpc [Accessed: May 02, 2024] A. P. Kourtis, K. Hatfield, J. Baggs et al. Vital signs: Epidemiology and recent trends in methicillin-resistant and in methicillin-susceptible Staphylococcus aureus bloodstream infections – United States. Morbidity and Mortality Weekly Report 2019 (68), 214-219 K. Hamed, M. Engelhardt, M. E. Jones et al. Ceftobiprole versus daptomycin in Staphylococcus aureus bacteremia: a novel protocol for a double-blind, Phase III trial. Future Microbiology 2020 (1), 35-48 J. Edelsberg, C. Taneja, M. Zervos et al. Trends in US hospital admissions for skin and soft tissue infections. Emerging Infectious Diseases 2009 (15), 1516-1518 J. A. Ramirez, T. L. Wiemken, P. Peyrani et al. Adults hospitalized with pneumonia in the United States: Incidence, epidemiology, and mortality. Clinical Infectious Diseases 2017 (65), 1807-1812 The content above comes from the network. if any infringement, please contact us to modify.

License out/inDrug ApprovalClinical Result

26 Apr 2024

·www.biospace.com

Bruker Further Enhances Clinical Microbiology & Infection Diagnostics Portfolio at ESCMID Global 2024 Conference

New MBT Pathfinder® IVD robot for automated MALDI Biotyper® target preparation New LiquidArray® MTB-XDR panel for simultaneous detection of M. tuberculosis complex bacteria, and their resistances to five WHO-recommended second-line drugs against multidrug-resistant tuberculosis Pending ELITech acquisition has received all regulatory clearances; closing now expected in the second quarter of 2024 BARCELONA, Spain--(BUSINESS WIRE)-- At the ESCMID Global 2024 conference, Bruker is enhancing its innovative diagnostic solutions in microbial identification, antimicrobial susceptibility testing (AST), early sepsis diagnostics, and other infectious disease assays. Simplifying microbiology and infectious disease diagnostics and workflows in the clinical laboratory is a key goal for Bruker in support of earlier and improved patient treatment decisions. This press release features multimedia. View the full release here: MBT Pathfinder® IVD with Feeder IVD (Photo: Business Wire) Microbial identification – towards automated sample preparation The latest MALDI Biotyper® workflow uses MBT Compass HT IVD software to increase throughput up to 600 samples per hour, and automated instrument tuning via IDealTune™. An optional workflow now offers semi-automated sample preparation via the MBT Pathfinder® IVD robot to avoid time-consuming, repetitive and error-prone manual tasks. Sepsis – when every minute counts When the correct antibiotic treatment for sepsis is given quickly, outcomes can improve dramatically. The IVD-CE MALDI Biotyper®, used in conjunction with the MBT Sepsityper® IVD Kit, can identify pathogens within 20 minutes from a positive blood culture bottle. Bruker offers additional clinical workflows for rapid functional antibiotic resistance testing, like the MBT STAR®-Carba IVD assay for the detection of carbapenemase activity. Antimicrobial susceptibility testing (AST) AST can indicate which antimicrobial regimen is effective for patients. Bruker’s UMIC® tests deliver accurate results for single antibiotics and combinations, and the MICRONAUT range offers AST of multiple antibiotics in a single test in a user-friendly workflow in compliance with CLSI/EUCAST recommendations. The UMIC® portfolio covers five antibiotics and combinations, namely colistin, piperacillin-tazobactam, vancomycin/teicoplanin, daptomycin and cefiderocol. In addition, Bruker is developing the new MBT-fAST assay for rapid AST of gram-negative bacteria from positive blood cultures directly on the MALDI Biotyper® platform. The MBT-fAST clinical studies are planned for the second half of 2024. Bruker also intends concurrent clinical studies for IVDR certification of lipid A-based colistin resistance detection. This and the on-going development of microbial species and subspecies differentiation based on lipid patterns will further enhance the value of the MALDI Biotyper® sirius system for clinical laboratories. The MALDI Biotyper® sirius stands out as the first MALDI-TOF mass spectrometry system for microbial identification that uses the negative ion mode for microbial lipid analysis. Currently, this feature is for Research Use Only (RUO), setting the stage for forthcoming clinical applications. Outbreak control The Bruker IR Biotyper® enables efficient microbial strain typing of bacteria and yeasts for real-time epidemiological surveillance for a range of disease-causing pathogens. During outbreak scenarios within hospitals, the IR Biotyper can help prevent the spread of hospital-acquired infections (HAI). The IR Biotyper® for hospital hygiene and infection control can be combined with the MALDI Biotyper® for microbial species identification. LiquidArray® – next-generation syndromic panels The new LiquidArray® Gastrointestinal syndromic panel facilitates the simultaneous detection of up to 26 pathogens responsible for gastroenteritis. This streamlines clinical decision-making by allowing the simultaneous analysis of multiple targets from a single sample. The rise of multidrug-resistant and extensively drug resistant M. tuberculosis strains has added complexity to TB diagnosis and treatment – and global travel is causing re-emergence in formerly low risk countries. Bruker’s new multiplex mycobacteria test LiquidArray® MTB-XDR VER 1.0, detects TB-causing bacteria of the M. tuberculosis complex and identifies resistance to five WHO-recommended second-line drugs. Dr. Wolfgang Pusch, President of the Bruker Microbiology & Infection Diagnostics division, commented: “Bruker is committed to innovation in routine microbiology and infectious disease testing. This includes nearly universal microbial identification with the MALDI Biotyper®, rapid blood culture analysis with the MBT Sepsityper® IVD Kit, early implementation of diagnostics for new antibiotics with our UMIC® portfolio, real-time epidemiological surveillance with the IR Biotyper®, and syndromic panels with our LiquidArray® assay portfolio.” Pending ELITechGroup Acquisition Regulatory Clearances As announced on February 28, 2024, Bruker Corporation has signed a Share Purchase Agreement to acquire ELITechGroup, excluding the ELITech clinical chemistry business. All regulatory clearances for this acquisition have now been received, and closing of the acquisition is expected during Q2 2024, subject to remaining closing conditions. About Bruker Corporation – Leader of the Post-Genomic Era (Nasdaq: BRKR) Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit . View source version on businesswire.com: Contacts Trade Press & Customer Contact: Philip Perry Senior Vice President, Marketing and Product Management Bruker Microbiology & Infection Diagnostics Division T: +49-172-313-7216 E: philip.perry@bruker.com Investor Contact: Justin Ward Sr. Director, Investor Relations & Corporate Development Bruker Corporation T: +1 (978) 313-5800 E: Investor.Relations@bruker.com Source: Bruker Corporation Smart Multimedia Gallery Photo MBT Pathfinder® IVD with Feeder IVD (Photo: Business Wire) Photo LiquidArray® MTB-XDR VER 1.0 (Photo: Business Wire) Logo View this news release and multimedia online at:

Acquisition

100 Deals associated with Daptomycin

External Link

KEGG	Wiki	ATC	Drug Bank
D01080	Daptomycin	J01XX09	DB00080

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Skin and skin structure infections	AU	Juno Pharmaceuticals Corp.Startup	23 Apr 2019
Endocarditis, Bacterial	JP	Merck Sharp & Dohme Corp.	01 Jul 2011
Secondary infection	JP	Merck Sharp & Dohme Corp.	01 Jul 2011
Sepsis	JP	Merck Sharp & Dohme Corp.	01 Jul 2011
Skin Diseases, Infectious	JP	Merck Sharp & Dohme Corp.	01 Jul 2011
Bacteremia	CN	Cubist Pharmaceuticals LLC	02 Sep 2009
Bacterial Infections	CN	Cubist Pharmaceuticals LLC	02 Sep 2009
Staphylococcal Infections	CN	Cubist Pharmaceuticals LLC	02 Sep 2009
Complicated skin and soft tissue infection	EU	Merck Sharp & Dohme BV	19 Jan 2006
Complicated skin and soft tissue infection	IS	Merck Sharp & Dohme BV	19 Jan 2006
Complicated skin and soft tissue infection	LI	Merck Sharp & Dohme BV	19 Jan 2006
Complicated skin and soft tissue infection	NO	Merck Sharp & Dohme BV	19 Jan 2006
Right sided infective endocarditis	EU	Merck Sharp & Dohme BV	19 Jan 2006
Right sided infective endocarditis	IS	Merck Sharp & Dohme BV	19 Jan 2006
Right sided infective endocarditis	LI	Merck Sharp & Dohme BV	19 Jan 2006
Right sided infective endocarditis	NO	Merck Sharp & Dohme BV	19 Jan 2006
Staphylococcus aureus bacteraemia	EU	Merck Sharp & Dohme BV	19 Jan 2006
Staphylococcus aureus bacteraemia	IS	Merck Sharp & Dohme BV	19 Jan 2006
Staphylococcus aureus bacteraemia	LI	Merck Sharp & Dohme BV	19 Jan 2006
Staphylococcus aureus bacteraemia	NO	Merck Sharp & Dohme BV	19 Jan 2006

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Osteomyelitis	Phase 3	-	-	13 Sep 2013
Bacteremia due to Methicillin resistant Staphylococcus aureus	Phase 3	FR	Novartis AG	01 May 2012
Cross Infection	Phase 3	FR	Novartis AG	01 May 2012
Febrile Neutropenia	Phase 3	US	-	01 Apr 2011
Fever	Phase 3	US	-	01 Apr 2011
Skin structures and soft tissue infections	Phase 3	-	Merck Sharp & Dohme Corp.	01 Sep 2008
Surgical Wound Infection	Phase 3	US	-	01 Jul 2008
Soft Tissue Infections	Phase 3	-	Novartis Pharmaceuticals Corp.	01 Apr 2006
Gram-Positive Bacterial Infections	Phase 3	-	-	19 Dec 2002
Community-acquired bacterial pneumonia	Phase 3	-	-	31 Oct 2000

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01199783 (CTgov)	Phase 3	Diabetic foot infection	1	Daptomycin (Daptomycin)	tachxsfxrn(qhfupalhsw) = ixjxpualkz agwoeymzkg (csetwxfgxp, rdhcgkyzwr - semxhveibj) View more	-	18 Mar 2024
				Vancomycin (Vancomycin)	xcfzyrpwjj(hgullhommi) = hvrhuifkdx vgekmteijx (jwztjgzrhy, nrtobfbvkh - fdfpwhjweh) View more
NCT04983901 (CTgov)	Phase 2	Malignant Solid Neoplasm \| Hematologic Neoplasms \| Febrile Neutropenia	100	Meropenem+Linezolid+Cefepime+Piperacillin-Tazobactam+Daptomycin+Vancomycin	zwvlqzegyv(dgoykozzen) = phkghyjoop nbqxdyymsn (qnmrdmrtnt, cugcbpjtxx - xonjfidkru) View more	-	12 Mar 2024
NCT01734694 (CTgov)	Phase 4	Arthritis, Infectious \| Endocarditis \| Bacteremia ... View more	100	Vancomycin (Vancomycin)	dlwdaimzph(iajdyqgzjn) = jxkhzppfvh qqywvzqsaz (thwdroygge, zozccrtpov - vywxgtgmys) View more	-	03 May 2023
				Ceftaroline+Linezolid+Daptomycin (Comparator)	dlwdaimzph(iajdyqgzjn) = wtbzydvaxi qqywvzqsaz (thwdroygge, afmakhblmv - xjokezudba) View more
Pubmed	Not Applicable	-	77	Daptomycin (Three-sample strategy)	uxfxqidznh(bbavapejgi) = hbpeatijja kclwiqwyvq (qvajldhdob )	-	03 Jan 2023
NCT03643952 (MK-3009-029 \| 3009-029, Pubmed \| J Infect Chemother) Manual	Phase 2	Skin structures and soft tissue infections \| Bacteremia	18	Daptomycin (cSSTI)	fpzdrcxmhi(nxjwsineuf) = cgchfiglyb aevopuwbog (rylrwwuytf )	Positive	01 Mar 2022
				Daptomycin (bacteremia)	fpzdrcxmhi(nxjwsineuf) = iyziqmmzjm aevopuwbog (rylrwwuytf )
NCT03643952 (MK-3009-029 \| 3009-029, CTgov)	Phase 2	Skin structures and soft tissue infections \| Bacteremia \| Skin Diseases, Infectious ... View more	18	Daptomycin for Injection	wsffkzchtu(ndkbndhrby) = arrtlvkzbs ztdolncbss (tgofjeyfhn, ahzzugjpoe - asfokhdmqa) View more	-	30 Mar 2021
NCT00467272 (CTgov)	Phase 2	Catheter-Related Infections \| Sepsis	30	Daptomycin	gvugbvzcfg(hewmkcodop) = rvafpwntqx dujbnsuept (qytvleeosu, molafixaoy - tojoxnwrqy) View more	-	08 Feb 2021
NCT01922011 (MK-3009-006, Pubmed \| Pediatr Infect Dis J) Manual	Phase 3	Osteomyelitis Pediatric Gram-Positive	146	Daptomycin	zfzsrzvmuy(ltcucbyzrr) = ledxtvsyme vzgdixiasp (ircfqfsund ) View more	Negative	01 Sep 2020
				vancomycin+ nafcillin+ equivalent	zfzsrzvmuy(ltcucbyzrr) = zcwxedsgdd vzgdixiasp (ircfqfsund ) View more
Pubmed \| Clin Infect Dis	Not Applicable	Staphylococcus aureus bacteraemia	115	Adjunctive Daptomycin	vspyobwofd(tbdgbxmhqc) = btwvrbzcrn tadgnbmthu (adsgnmyzvu ) View more	Negative	15 Jul 2020
				Placebo	vspyobwofd(tbdgbxmhqc) = vklgfvzzig tadgnbmthu (adsgnmyzvu ) View more
NCT02660346 (Pubmed \| Antimicrob Agents Chemother)	Phase 4	MRSA - Methicillin resistant Staphylococcus aureus infection	40	Standard monotherapy	jpuspfeezb(lazxpsveqo) = orggwxtaqw vaumvzvvvs (mriwonbafw )	-	01 May 2019

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis